Tarsus Pharmaceuticals (TARS) Current Assets (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Current Assets of $537.2 million for Q1 2026, up 11.74% year-over-year from $480.8 million in Q1 2025, and up 2.76% quarter-over-quarter from $522.8 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Current Assets (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Current Assets history runs 8 years deep, the most recent figure standing at $537.2 million for Q1 2026.
- In Q1 2026, Current Assets rose 11.74% year-over-year to $537.2 million; the TTM figure through Mar 2026 stood at $537.2 million (up 11.74% YoY), while the FY2025 annual figure was $522.8 million, up 46.56% from the prior year.
- Current Assets for Q1 2026 stood at $537.2 million, up from $522.8 million in the prior quarter.
- The five-year high for Current Assets was $537.2 million in Q1 2026, with the low at $178.8 million in Q1 2022.
- The 5-year median for Current Assets is $340.7 million (2024), against an average of $337.1 million.
- The sharpest annual moves came in 2023 and 2024: Current Assets fell 26.69% in 2023, then surged 97.62% in 2024.
- Tarsus Pharmaceuticals' Current Assets stood at $225.4 million in 2022, then increased by 13.65% to $256.1 million in 2023, then soared by 39.27% to $356.7 million in 2024, then surged by 46.56% to $522.8 million in 2025, then increased by 2.76% to $537.2 million in 2026.
- Business Quant data shows TARS's Current Assets at $537.2 million in Q1 2026, $522.8 million in Q4 2025, and $501.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 561.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 561.99 Mn |
| Mar 31, 2026 | 537.23 Mn |
| Dec 31, 2025 | 522.78 Mn |
| Sep 30, 2025 | 501.70 Mn |
| Jun 30, 2025 | 474.43 Mn |
| Mar 31, 2025 | 480.77 Mn |
| Dec 31, 2024 | 356.71 Mn |
| Sep 30, 2024 | 357.12 Mn |
| Jun 30, 2024 | 362.59 Mn |
| Mar 31, 2024 | 340.72 Mn |
| Dec 31, 2023 | 256.13 Mn |
| Sep 30, 2023 | 259.28 Mn |
| Jun 30, 2023 | 183.48 Mn |
| Mar 31, 2023 | 208.65 Mn |
| Dec 31, 2022 | 225.38 Mn |
| Sep 30, 2022 | 234.08 Mn |
| Jun 30, 2022 | 250.28 Mn |
| Mar 31, 2022 | 178.76 Mn |
| Dec 31, 2021 | 175.95 Mn |
| Sep 30, 2021 | 187.09 Mn |